Balaxi Pharmaceuticals Limited Fundamental Analysis (NSE: BALAXI.NS)
Balaxi Pharmaceuticals Limited Fundamental Analysis (NSE: BALAXI.NS)
Balaxi Pharmaceuticals Limited (NSE: BALAXI.NS) shows weak financial fundamentals with a PE ratio of 49.78, profit margin of 0.86%, and ROE of 1.01%. The company generates $2.8B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BALAXI.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakBALAXI.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateBALAXI.NS shows balanced valuation metrics.
Growth Score
WeakBALAXI.NS faces weak or negative growth trends.
Financial Health Score
ExcellentBALAXI.NS maintains a strong and stable balance sheet.
Profitability Score
ModerateBALAXI.NS maintains healthy but balanced margins.
Key Financial Metrics
Is BALAXI.NS Expensive or Cheap?
P/E Ratio
BALAXI.NS trades at 49.78 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BALAXI.NS's PEG of -0.57 indicates potential undervaluation.
Price to Book
The market values Balaxi Pharmaceuticals Limited at 0.50 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.38 times EBITDA. This is generally considered low.
How Well Does BALAXI.NS Make Money?
Net Profit Margin
For every $100 in sales, Balaxi Pharmaceuticals Limited keeps $0.86 as profit after all expenses.
Operating Margin
Core operations generate 2.38 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.01 in profit for every $100 of shareholder equity.
ROA
Balaxi Pharmaceuticals Limited generates $0.72 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Balaxi Pharmaceuticals Limited generates limited operating cash flow of $149.66M, signaling weaker underlying cash strength.
Free Cash Flow
Balaxi Pharmaceuticals Limited generates weak or negative free cash flow of $25.78M, restricting financial flexibility.
FCF Per Share
Each share generates $0.47 in free cash annually.
FCF Yield
BALAXI.NS converts 2.08% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
49.78
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.57
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.50
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.44
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.51
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.007
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How BALAXI.NS Stacks Against Its Sector Peers
| Metric | BALAXI.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 49.78 | 30.97 | Worse (Expensive) |
| ROE | 1.01% | 515.00% | Weak |
| Net Margin | 0.86% | 30197.00% | Weak |
| Debt/Equity | 0.23 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 4.51 | 5.71 | Strong Liquidity |
| ROA | 0.72% | -16.00% (disorted) | Weak |
BALAXI.NS outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Balaxi Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation